Open AccessZidovudine-Based Treatments Inhibit the Glycosylation of ADAM17 and Reduce CD163 Shedding From Monocytes
Author(s) -
Song Chen,
Xiaoyu Wang,
Haipeng Zhu,
Qin Tang,
Wei Du,
Hanwen Cao,
Cheng-Chou Lai,
Weizhong Guo,
Linchun Fu,
Wei Lü
Publication year - 2018
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000001769
Subject(s) - cd163 , zidovudine , cd16 , monocyte , cd14 , flow cytometry , glycosylation , immunology , pharmacology , medicine , biology , macrophage , human immunodeficiency virus (hiv) , antigen , biochemistry , viral disease , cd8 , cd3 , in vitro
sCD163, a biomarker of monocyte-macrophage activation, has been identified as a predictor of all-cause mortality in treated HIV-infected individuals. Nevertheless, little is known about whether different antiretroviral drugs differentially regulate sCD163 levels and monocyte activation.